IDESPHARMA
ActiveSummary
IDESPHARMA has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €353,392 and a net result of -€6,436. Equity is growing by about 27% per year across the filed financial years. Its solvency ranks better than 38% of 12,482 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2025
04-12
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
30-09
Financial
Weakest financial yearnet -€6,436
Net result drops to -€6,436, the lowest in the series.
2024
13-12
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
08-01
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
30-09
Financial
Equity above €200,000equity €262,562 ▲78.1%
A profit in every financial year since 2022 builds equity to €262,562.
20-03
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.